Skip to main content

ORACEA Capsules Provide Multiple Benefits Over Doxycycline 100 mg2,3 ORACEA Capsules Doxycycline 100 mg

Superior GI tolerability compared to 100 mg2

In a head-to-head clinical study, no nausea, diarrhea or vomiting were reported for ORACEA Capsules (vs 17.3%, 4.3% and 4.3% for doxycycline 100 mg)

 Yes No

No evidence of bacterial resistance in a 9-month study3

ORACEA Capsules are precisely formulated (30 mg immediate release/10 mg delayed release) to treat the inflammatory lesions associated with rosacea without increasing the risk of antibiotic resistance.

 Yes No

No photosensitivity or vaginal candidiasis reported in controlled clinical studies3

 Yes No

In pivotal clinical studies, the most common treatment-related adverse events (>2%) for ORACEA Capsules were nasopharyngitis (4.8%), diarrhea (4.5%), hypertension (3%), sinusitis (2.6%), and aspartate aminotransferase increase (2.2%).

Offer your patients the benefits of a sub-antimicrobial dose

With fewer overall GI disease (GID) comorbidities vs conventional (50 mg/100 mg) dose doxycycline, the GID event rate for a sub-antimicrobial dose was comparable to no doxycycline4

Association Between GID and Doxycycline Dosage4*

Prevalence of GID was 38% Lower with SD† doxycycline‡ vs CD§ doxycycline 100 mg** 0.62†† (0.58-0.67); P<0.0001

SD doxycycline demonstrated 20% Lower prevalence in GID vs CD doxycycline 50 mg‡‡ 0.80 (0.73-0.88); P<0.0001

GID events were Not Significantly Different between SD doxycycline and no doxycycline use§§ (P=0.16) 1.05 (0.98-1.12); P=0.16

CD doxycycline*** was 53% more likely to be associated with GID vs no doxycycline use 1.53 (1.48-1.58); P<0.0001

  • *A cross-sectional study of individuals with a history of rosacea between 2007-2015 (n=77,177) was conducted to examine the association between doxycycline treatments (40, 50, 100 mg, and no doxycycline) and 10 gastrointestinal diseases4
  • †Sub-antimicrobial dose
  • ‡Rosacea population aged 30-64 with SD-doxycycline intake (n=4,835).
  • §Conventional dose
  • **Rosacea population aged 30-64 with CD-doxycycline intake 100 mg intake (n=18,953).
  • ††Adjusted odds ratios (aOR) were computed using logistic regression, adjusted for age and sex, and 95% confidence intervals were used
  • ‡‡Rosacea population aged 30-64 with CD-doxycycline intake 50 mg intake (n=3,142)
  • §§Rosacea population aged 30-64 without CD-doxycycline intake and without SD-doxycycline intake (n=50,492)
  • ***Rosacea population aged 30-64 with standard dose (50 or 100 mg), CD-doxycycline intake and without sub-antimicrobial dose, modified release doxycycline intake (n=21,790)

Help your patients see a positive difference

Not actual patients. Individual results may vary. Results are simulated to show average improvement in clinical trials.

IGA (Investigator’s Global Assessment) Scale

  • 4 - Severe

    Numerous small and/or large papules/pustules, severe erythema

  • 3 - Moderate

    Several small or large papules/pustules, moderate erythema

  • 2 - Mild

    Few small papules/pustules, mild

  • 1 - Almost Clear

    Very few small papules/pustules, very mild erythema present

  • 0 - Clear

    No inflammatory lesions present, no erythema

Antibiotic Resistance

ORACEA Capsules are precisely formulated (30 mg immediate release/10 mg delayed release) beads to treat the inflammatory lesions associated with rosacea and did not increase the risk of antimicrobial resistance in a 9 month study.

Learn More